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The profibrotic adhesion molecule, osteopontin (OPN), is
upregulated in kidneys of humans and mice with diabetes.
The thiazolidinedione (TZD) insulin sensitizers decrease
albuminuria in diabetic nephropathy (DN) and reduce OPN
expression in vascular and cardiac tissue. To examine
whether OPN is a critical mediator of DN we treated db/db
mice with insulin, rosiglitazone, or pioglitazone to achieve
similar fasting plasma glucose levels. The urine albumin-to-
creatinine ratio and glomerular OPN expression were
increased in diabetic mice, but both were reduced by the
TZDs more than by insulin. We administered streptozotocin
to OPN-null and OPN-wild-type mice, and OPN-null mice
were bred into both type 1 (Ins2akita/þ ) and 2 (db/db)
diabetic mice. In each case, OPN deletion decreased
albuminuria, mesangial area, and glomerular collagen IV,
fibronectin and transforming growth factor (TGF)-b in the
diabetic mice compared with their respective controls. In
cultured mouse mesangial cells, TZDs but not insulin
decreased angiotensin II-induced OPN expression, while
recombinant OPN upregulated TGF-b, ERK/MAPK, and JNK/
MAPK signaling. These studies show that OPN expression
in DN mouse models enhances glomerular damage, likely
through the expression of TGF-b, while its deletion protects
against disease progression, suggesting that OPN might
serve as a therapeutic target.
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Activation of the nuclear receptor peroxisome proliferator-
activated receptor-g (PPARg) in the kidney attenuates
albuminuria in animal models of both type 1 and 2 diabetes
and in humans with type 2 diabetes.1–4 However, the
mechanisms mediating these antialbuminuric effects are not
known, but appear to be independent of blood glucose and
blood pressure.1,3 Recently, osteopontin (OPN), a large
phosphoglycoprotein adhesion molecule, has emerged as a
potentially key pathophysiologic contributor in diabetic
nephropathy (DN). OPN is expressed in all glomerular cells:
mesangial cells, podocytes, and endothelial cells.5–8 Micro-
array analyses of diabetic versus normal kidneys identified
OPN as one of the major genes upregulated in humans with
DN and in mice with either type 1 diabetes induced by
streptozotocin (STZ) or the type 2 db/db model of diabetes.9
Ligands to PPARg, thiazolidinediones (TZDs), suppress OPN
expression in cardiomyocytes, vascular smooth muscle cells,
and macrophages to attenuate cardiac fibrosis and athero-
sclerosis.10,11 We, therefore, hypothesized that OPN is a
critical mediator in DN and that the renal protective effect of
TZDs in DN may involve suppression of OPN. To address
this hypothesis, we (1) determined whether glomerular OPN
expression correlated with attenuation of albuminuria in
db/db mice treated with TZDs versus insulin, (2) defined the
role of OPN in STZ-induced albuminuria using OPN
knockout mice, (3) examined the effect of genetic knockout
of OPN in mouse models of both type 1 and 2 diabetes, and
(4) investigated OPN regulation by angiotensin II (AngII)
and TZDs, and the effect of mouse recombinant OPN on
transforming growth factor (TGF)-b expression and signal
transduction in cultured mouse mesangial cells.
RESULTS
Thiazolidinediones improve renal changes in db/db mice
more than insulin
Fasting plasma glucose was elevated in db/db mice versus
db/m mice and remained unchanged after treatment with
PPARg ligands, rosiglitazone or pioglitazone, or with insulin
for 8 weeks, similar to pretreatment levels, but progressively
increased in db/db control mice (Table 1). Initial and final
blood pressures did not change among all animal groups.
Before killing, db/db mice weighed significantly more than
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db/m mice. The ratio of body weight/tibia length was
comparable in control, rosiglitazone- and pioglitazone-
treated db/m and higher in db/db mice (Table 1). The ratio
of kidney weight/tibia length was not different among the
animals (data not shown).
Baseline albumin-to-creatinine ratio (ACR) was elevated
in 8-week-old db/db mice (B400–700 mg/dl) and progres-
sively increased to 1207±72 mg/mg by 16 weeks, Po0.05, as
previously reported in this model.12 ACR in db/m mice
(B100 mg/dl) was unchanged from initial levels (Figure 1).
Insulin treatment decreased ACR in db/db mice to
458±107 mg/mg. However, the TZDs had a greater effect to
lower ACR (rosiglitazone, 217±50 mg/mg; pioglitazone,
233±26 mg/mg), Po0.05. Thus, PPARg ligands improved
ACR more than did insulin, suggesting a PPARg effect on
albumin excretion beyond the decrease in glucose.
Periodic acid Schiff (PAS) staining was performed to
quantify the % mesangial area that was glomerular mesangial
matrix (Figures 2a, b). There was no significant difference
among the db/m group. However, % mesangial area was
significantly higher in db/db control compared with insulin-
treated mice, which was also significantly higher than in
either rosiglitazone- or pioglitazone-treated mice. Immuno-
histochemistry (IHC) for glomerular fibronectin was per-
formed to assess matrix protein accumulation. Glomerular
fibronectin staining was similar to % mesangial area (Figures
2c, d) withB6-fold increase in db/db control mice, a modest
reduction with insulin treatment and a greater reduction
by TZDs. Glomerular cores were isolated from a subset of
animals to determine TGF-b protein expression. TGF-b levels
were higher in db/db control and insulin-treated db/db
compared with either db/m control or rosiglitazone-treated
db/db mice, Po0.05 (Figure 2e, f).
PPARc ligands differentially regulate glomerular OPN
compared with insulin
Glomerular expression of OPN was substantially increased in
db/db mice compared with db/m mice, similar to that in
whole kidney of humans and animals.9 There was a trend for
insulin to decrease glomerular OPN expression after 8 weeks.
In contrast, OPN expression was reduced by 40–50% in
rosiglitazone- and pioglitazone-treated db/db mice, Po0.05
(Figure 3a). These observations suggested that glomerular
OPN may be a potential target for PPARg ligands, with a
more modest effect of insulin.
We incubated stable mouse mesangial cells with AngII in
the absence and presence of insulin, rosiglitazone, or
pioglitazone to examine their direct effects on OPN
expression. Quantitative reverse transcriptase-polymerase
chain reaction (RT-PCR) demonstrated B2-fold stimulation
of OPN by AngII and 1.5-fold upregulation by insulin þ
AngII compared with untreated control cells, Po0.05.
However, both rosiglitazone and pioglitazone downregulated
OPN in the presence of AngII, to control levels, Po0.05.
Insulin alone did not alter OPN expression in AngII-treated
cells (Figure 3b).
Genetic deletion of OPN attenuates albuminuria and
glomerular matrix, collagen IV, fibronectin, and TGF-b in
STZ type 1 diabetes
To determine the role of OPN in DN, we induced diabetes in
OPN/ and OPNþ /þ control mice, on a 129Black Swiss
background, with STZ to achieve plasma glucose levels of
B450 to 600 mg/dl compared with control mice (B100 mg/dl),
Table 1 | Physiological features of treated and untreated non-diabetic db/m and diabetic db/db mice
db/m Control db/db Diabetic
Pio Rosi Control Pio Rosi Insulin Control
Number of mice 6 4 8 12 8 8 20
Initial plasma glucose (mg/dl) 92±4 74±4 81±4 271±31a 279±27a 299±39a 283±23a
Final plasma glucose (mg/dl) 134±16 114±15 115±11 291±18a 249±22a 278±44a 649±17b
Initial SBP (mmHg) 98±7 100±4 100±7 92±6 104±3 103±3 97±5
Final SBP (mmHg) 109±6 100±5 111±3 108±11 100±4 98±3 93±3
Body weight/tibia length (g/mm) 1.4±0.01 1.5±0.03 1.4±0.03 3.8±0.09a 3.0±0.05a 3.0±0.07a 2.9±0.05a
Abbreviations: Pio, pioglitazone; Rosi, rosiglitazone; SBP, systolic blood pressure.
aDiabetic db/db versus non-diabetic db/m control, Po0.05.
bFinal versus initial, Po0.05.
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Figure 1 |PPARc ligands improved albumin-to-creatinine
ratio (ACR) more than insulin. Diabetic db/db and non-diabetic
db/m mice (4–20 animals per group) were fed chow (Control)
or treated with pioglitazone (Pio), rosiglitazone (Rosi) or insulin for
8 weeks. Animals were placed in metabolic cages for urine collection
at age 8 weeks (initial) and at the end of the study (age 16 weeks),
and albumin-to-creatinine ratio was measured, *Po0.05.
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Po0.05 (Table 2). There were no differences in tail-cuff
systolic blood pressures over the 12-week study. At killing,
body weight/tibia length was significantly higher in non-
diabetic compared with diabetic mice, Po0.05. Kidney
weight/tibia length was slightly less in the non-diabetic
versus the diabetic OPNþ /þ , Po0.05, but remained un-
changed in OPN/mice.
The initial ACR was higher in OPNþ /þ compared with
OPN/mice, Po0.05 (Figure 4a). After 4, 8, and 12 weeks
of STZ administration, the diabetic OPN/ had higher ACR
compared with non-diabetic OPNþ /þ mice. However, ACR
in diabetic OPNþ /þ was substantially higher than in diabetic
OPN/ mice throughout the study. Thus, the lack of OPN
attenuated albuminuria after STZ administration, despite
similar plasma glucose levels.
To further investigate the effect of OPN on the pathology
of DN, kidneys were sectioned for PAS and IHC staining,
and glomerular cores were isolated for western blots.
STZ-diabetic OPNþ /þ had greater glomerular % mesangial
area (1.9-fold), collagen IV (2.5-fold), TGF-b (1.6-fold), and
fibronectin (1.2-fold) expression compared with non-dia-
betic OPNþ /þ mice, Po0.05 (Figures 4b–i). Collagen, TGF-b,
and fibronectin protein levels were not different in STZ-
diabetic OPN/ versus non-diabetic OPN/ mice. Quan-
titative RT-PCR of glomerular core collagen IV, fibronectin,
and TGF-b expression showed parallel results (data not
shown). Thus, the lack of OPN is associated with less
albuminuria as well as less glomerular matrix, collagen IV,
TGF-b, and fibronectin mRNA and protein, suggesting
that OPN may have a pathophysiologic role in glomerular
injury in diabetes.
OPN deletion in Ins2akita/þ and Leprdb/db mice attenuates
albuminuria, glomerular matrix, collagen IV, fibronectin, and
TGF-b
To further test the role of OPN in genetic models of types 1
and 2 DN, OPN/ mice were bred onto Ins2akita/þ ; Ins2þ /þ
and (Leprdb/db; Leprþ /þ mice) (Figures 5 and 6). Quantitative
RT-PCR of glomerular cores confirmed the absence of OPN
expression in OPN/ mice (data not shown). In both
groups, initial and final plasma glucose was significantly
lower in non-diabetic (OPNþ /þ Ins2þ /þ ; OPN/Ins2þ /þ
and OPNþ /þLeprþ /þ ; OPN/Leprþ /þ ) compared with
diabetic (OPNþ /þ Ins2akita/þ ; OPN/Ins2akita/þ , and
OPNþ /þLeprdb/db; OPN/Leprdb/db) mice, Po0.05. There
were no differences in initial or final blood pressures among
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db/m db/db Rosi db/db Insdb/db Figure 2 |Periodic acid Schiff stain, % mesangial area,
fibronectin and TGF-b expression of treated db/db mice. After
8 weeks of treatment with pioglitazone (Pio), rosiglitazone (Rosi),
insulin or chow-fed Control, db/db and db/m mice were killed.
(a) Kidneys were harvested, fixed in 4% paraformaldehyde, and
3 mm sections were stained with Periodic acid Schiff (PAS). (b) PAS-
positive tissue was quantified as % of total mesangial area
measured by optical microscopy image analyses, *Po0.05. (c)
Kidney sections were used for immunohistochemical staining for
fibronectin. Stained Control section shows lack of staining.
(d) Positive staining for fibronectin in the glomeruli was quantified
by optical microscopy. NS: not significant, *Po0.001. (e) Protein
obtained from isolated glomerular cores was used for western
blot analysis of TGF-b expression using autoradiography and
(f) quantified by densitometry. The figure shows a representative
blot (top panel) and bar graph obtained from densitometric
analysis of several blots, *Po0.05 (db/m control n¼ 8, db/db
control n¼ 9, db/db Rosi n¼ 4, db/db Ins n¼ 4).
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the groups. However, there was a significant increase in body
weight and kidney weight/tibia length between Leprdb/db and
Leprþ /þ mice, Po0.05 (Tables 3 and 4).
The protective effect of OPN depletion against albumi-
nuria was demonstrated in genetic type 1 and 2 OPN/
mice. ACR was 5- to 7.7-fold higher in OPNþ /þ Ins2akita/þ
versus OPNþ /þ Ins2þ /þ but not different in OPN/
Ins2akita/þ versus OPN/Ins2þ /þ mice at 2, 3, and 4
months, Po0.05. Similarly, ACR was B9-fold higher in
OPNþ /þLeprdb/db versus OPNþ /þLeprþ /þ and three- to
fourfold higher in OPN/Leprdb/db versus OPN/Leprþ /þ
mice, Po0.05. OPN deletion attenuated ACR two- to
threefold in both genetic OPN/-diabetic mice, Po0.05
(Figures 7a, b).
OPN deletion markedly attenuated the diabetes-induced
increases in % mesangial area (B1.3-fold), collagen IV
(B1.5-fold), and fibronectin (four to fivefold) in both
diabetic models by PAS and IHC, Po0.05 (Figures 8a–l;
Po0.001). Glomerular TGF-b by quantitative RT-PCR
showed B2-fold lower expression in both OPN/-diabetic
models versus diabetic OPNþ /þ mice, Po0.01 and there
was no increase in TGF-b expression in diabetic versus non-
diabetic OPN/ mice (Figures 8m, n).
OPN stimulates TGF-b, ERK/MAPK, and JNK signal
transduction in mesangial cells
To investigate the cellular effect of OPN, cultured mesangial
cells were incubated with recombinant mouse OPN (rmOPN)
for up to 24 h. There was a dose-dependent increase in TGF-b
expression with OPN up to 10 nM (Figure 9a, b). At 10 nM,
there was a time-dependent upregulation of OPN by TGF-b
(Figure 9c, d), which peaked at 12 h. In contrast, pretreatment
of mesangial cells grown in high glucose (30 mM) with antibody
against OPN resulted in a dose-dependent inhibition of TGF-b
expression (Figure 9e, f). These data suggested that OPN
enhances TGF-b expression, and that OPN may promote
glomerular matrix accumulation by upregulation of TGF-b.
Several studies have shown that mitogen-activated protein
kinase (MAPK) signaling pathways are activated in mesangial
cells in the diabetic milieu. To understand the potential
mechanisms by which OPN may regulate extracellular
matrix expression and thus identify a potential link to
promote albuminuria in the glomerulus, mesangial cells were
preincubated with inhibitors of ERK/MAPK (PD98059) and
JNK/MAPK (SP600125) for 30 min followed by incubation
with rmOPN for 30 and 45 min, respectively. Phosphorylated
ERK and phosphorylated JNK were upregulated two- to
threefold by rmOPN, Po0.05. However, only ERK and not
JNK expression was significantly inhibited after preincuba-
tion with the inhibitor (Figures 10a–d). As c-Jun is
phosphorylated by JNK at serine 63,13 we looked at the
expression of c-Jun to determine whether the ability of
activated JNK to phosphorylate c-Jun is altered. We showed a
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Figure 3 |PPARc ligands and insulin differentially regulate
osteopontin. At the end of the study, mRNA was isolated
from glomerular cores of db/m and db/db mice treated
with pioglitazone (Pio), rosiglitazone (Rosi), insulin or control.
(a) Quantitative RT-PCR analysis of osteopontin (OPN) expression
was performed; *Po0.05 versus db/db control, #Po0.05 versus db/db
insulin, n¼ 4–6. (b) Mouse mesangial cells were preincubated
with Pio (5 mmol/l) or Rosi (5 mmol/l) followed by treatment
with angiotensin II (AngII; 1 mmol/l) or insulin (1 mmol/l); n¼ 2–3,
*Po0.05 versus untreated control cells.
Table 2 | Physiological characteristics of OPN+/+ and OPN/ mice
OPN+/+ OPN/
Control Diabetic Control Diabetic
Number of mice 10 13 8 10
Initial plasma glucose (mg/dl) 63±4 68±4 73±7 68±3
Final plasma glucose (mg/dl) 93±5a 601±24a 102±8a 462±56a
Initial SBP (mmHg) 93±5 100±5 94±6 88±4
Final SBP (mmHg) 101±3 97±4 101±5 105±2
Body weight/tibia length (g/mm) 1.9±0.1b 1.4±0.1 1.9±0.0b 1.6±0.1
Kidney weight/tibia length (g/mm) 0.01±0.0b 0.02±0.0 0.01±0.0 0.01±0.0
Abbreviation: SBP, systolic blood pressure.
aFinal versus initial, Po0.05.
bControl versus diabetic, Po0.05.
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significant downregulation of phosphorylated c-Jun, Po0.05
(Figures 10e, f) suggesting that OPN impacts the downstream
activity of JNK. These results are in keeping with previous
investigation in osteoblastic cells, in which activation of
ERK/MAPK and c-Jun occurred during cellular adhesion
to OPN-coated plates.14
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DISCUSSION
In this investigation, two PPARg ligands, rosiglitazone and
pioglitazone, attenuated albuminuria in the db/db C57BLKS/Jlepr
mouse which, to date, is one of the better known models
of human type 2 DN.12,15 Although insulin administration
to db/db mice lowered plasma glucose to the levels
comparable to TZDs, it did not attenuate albuminuria to
the same extent as PPARg activation. In previous studies,
TZDs decreased albuminuria in humans and db/db mice
better than other oral antihyperglycemic agents16–18 and
are effective in STZ-treated mice without changes in
plasma glucose.3 Our and other observations that PPARg is
expressed in mesangial cells help to explain these findings,
although the mechanisms for the TZD effect has been
obscure.3 In vitro, PPARg activation impaired mesangial
cell growth; TGF-b, plasminogen-activator inhibitor-1 and
vascular endothelial growth factor production; and TGF-b
activity.3,19,20 We found that TZD or insulin adminis-
tration both decreased glomerular OPN expression in db/db
mice across all treatment groups, but OPN was reduced
to a greater extent by the TZDs, paralleling their effects
on albuminuria. The decrease in glomerular OPN in vivo can
be attributed, at least in part, to glucose lowering, as OPN
expression is increased by hyperglycemia.21,22 However, this
study suggests that TZDs suppress OPN expression beyond
glucose lowering. In cultured mesangial cells, TZDs sup-
pressed AngII-induced OPN expression, whereas insulin had
no effect. Thus, TZDs have direct actions to inhibit mesangial
OPN production, whereas the insulin effect in vivo is likely
mediated through glucose lowering.
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Figure 5 |Breeding protocol for OPN/ Ins2akita/þ .
OPN–/– × Leprdb/+
OPN+/– (50%) 
OPN+/–Leprdb/+ (25%) OPN+/–(25 %) OPN–/–Leprdb/+ (25%)
OPN–/– × OPN+/–Leprdb/+ (50%)
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Figure 6 |Breeding protocol for OPN/ Leprdb/db.
Figure 4 | STZ-diabetic OPN knockout mice have significantly reduced albumin-to-creatinine ratio (ACR), glomerular extracellular
matrix protein and TGF-b expression. Osteopontin wild-type (OPNþ /þ ) and knockout (OPN/) mice on a 129  Black Swiss background
were made diabetic with streptozotocin (STZ) and assessed for 12 weeks. (a) Mice were placed in metabolic cages for 24 h urine collection
to obtain ACR (mean±s.d.); *Po0.001, #Po0.01, NS: not significant. (b–e) Kidney sections from treated and untreated mice were used
for PAS and IHC staining for matrix accumulation, collagen IV and positive staining was quantified by optical microscopy image analyses,
*Po0.05. (f–i) Protein from glomerular cores of streptozotocin (STZ)-induced diabetic and non-diabetic osteopontin wild-type control
(OPNþ /þ ) and knockout (OPN/) mice was used in western blots for TGF-b and fibronectin (FN) and standardized to b-actin. Representative
western blots (top panels) of TGF-b and FN expression and densitometric analyses (bottom panels) are shown; *Po0.05, n¼ 4–8. ACR,
albumin-to-creatinine ratio; IHC, immunohistochemistry.
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To define the role of OPN in albuminuria, we induced
STZ diabetes in OPN-null mice, which were on a mixed
background. As STZ has been suggested to cause renal
damage beyond its diabetogenic effect, we studied OPN
effects in the Ins2akita/þ type 1 diabetic mouse, which has a
severe insulin deficiency due to a b-cell insulin processing
defect with subsequent renal damage (http://www.amdcc.
org). STZ-diabetic OPN/ mice developed albuminuria
that was only 20–50% of diabetic OPNþ /þ , which was
associated with decreased glomerular collagen, fibronectin,
and TGF-b, suggesting decreased renal profibrotic changes.
Similarly, loss of OPN in the Ins2akita/þ resulted in ACRs that
were 30–50% of diabetic controls and attenuated the
diabetes-induced increase in glomerular TGF-b and extra-
cellular matrix proteins. Deletion of OPN in the genetic
Leprdb/db type 2 diabetic mouse also caused a 30% reduction
in albuminuria and was similarly associated with decreased
glomerular collagen, fibronectin, and TGF-b expression.
Thus, in three strains of diabetic mice, loss of OPN resulted
in substantial reduction of albuminuria and mesangial
fibrosis, demonstrating a critical role of OPN in DN. It is
important to note here that as mixed backgrounds were used
in these studies, genetic differences in the mice cannot be
fully excluded as explanations for some of the effects
observed. However, the in vitro data appear to support the
in vivo observations. Addition of rmOPN to mesangial cells
resulted in a dose- and time-dependent stimulation of
TGF-b, whereas OPN antibodies inhibited the hyperglycemia-
induced rise in OPN. Taken together, these results suggest
that OPN is a key profibrotic factor contributing to
the development of glomerulosclerosis and albuminuria in
diabetes.
OPN was first isolated from bone23–25 and later identified
in other tissues and cells, including the vasculature, heart, as
well as renal tubules and glomerular epithelial cells, and
several body fluids suggesting it is secreted by cells.26,27 Its
diverse functions regulate tissue calcification and promote
inflammation, tissue remodeling, fibrosis, and angiogenesis.28
Many of these effects are mediated by the binding of OPN to
cell surface integrin receptors, such as anb1, anb3, anb5,
which activate intracellular signaling pathways.29 In the
kidney, OPN appears to be protective against accumulation
of calcium oxalate stones.30–32 However, it has been
associated with renal diseases characterized by tubulointer-
stitial fibrosis and proteinuria, as well as DN.33–35
The finding that OPN is differentially regulated by PPARg
ligands is of interest. The beneficial renal effect of PPARg
agonists in type 2 diabetes is likely mediated in part through
their antiglycemic effect.18 Treatment with rosiglitazone can
improve glomerular filtration rate, filtration fraction, and
endothelial function, possibly by increased nitric oxide bio-
availability36 TZDs also inhibit podocyte apoptosis,37 which
contributes to albuminuria and progressive proteinuria.38–40
Thus, several mechanisms potentially contribute to the
Table 3 | Physiological features of diabetic Ins2akita/+ and non-diabetic Ins2+/+ mice
OPN+/+ OPN/
Ins2+/+ Non-diabetic Ins2akita/+ Diabetic Ins2+/+ Non-diabetic Ins2akita/+ Diabetic
Number of mice 10 7 7 8
Initial plasma glucose (mg/dl) 95±3 480±34a 73±12 453±40a
Final plasma glucose (mg/dl) 117±3.5 465±34a 114±10 468±41a
Initial SBP (mmHg) 100±5 94±6 92±3 104±3
Final SBP (mmHg) 97±4 108±4 96±5 95±5
Body weight/tibia length (g/mm) 1.8±0.06 1.24±0.04 2.02±0.07 1.34±0.03
Kidney weight/tibia length (g/mm) 0.012±0.000 0.014±0.001 0.012±0.000 0.0129±0.000
Abbreviation: SBP, systolic blood pressure.
Initial: age 2 months.
Final: age 4 months.
aPo0.05, diabetic versus control mice.
Table 4 | Physiological features of OPN/Lepr and OPN+/+Lepr non-diabetic and diabetic mice
OPN+/+ OPN/
Lepr+/+ Non-diabetic Leprdb/db Diabetic Lepr+/+ Non-diabetic Leprdb/db Diabetic
Number of mice 9 7 9 15
Initial plasma glucose (mg/dl) 97±7 417±50a 85±5 497±35a
Final plasma glucose (mg/dl) 116±4 555±29a,b 86±9c 499±22a
Initial SBP (mmHg) 106±4 100±5 107±4 109±4
Final SBP (mmHg) 105±4 101±4 115±±4 109±4
Body weight/tibia length (g/mm) 1.70±0.06 2.80±0.18a 1.78±0.09 2.60±0.17a
Kidney weight/tibia length (g/mm) 0.012±0.001 0.015±0.001a 0.011±0.001 0.015±0.001a
Abbreviation: SBP, systolic blood pressure.
Initial: age 2 months.
Final: age 4 months.
aPo0.05, diabetic versus non-diabetic.
bPo0.05, final versus initial.
cPo0.05, OPN/ versus OPN+/+.
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protective effects of TZDs in DN in addition to their action
to suppress glomerular OPN.
PPARg ligands attenuate inflammatory gene expression by
inhibition of AP-1 and nuclear factor-kB sites.41 Recently,
Pascual et al.42 identified a novel mechanism of active
gene repression: PPARg ligands prevented removal of the
corepressor NCOR from an inflammatory response gene
promotor by preventing the recruitment of the proteosome
machinery, which normally degrades NCOR by ubiquityla-
tion. Active corepresssion did not involve a PPARg response
element. Although, the OPN promoter does not have a
PPARg response element or nuclear factor-kB site, it does
have multiple AP-1 sites.43–45 Troglitazone was reported to
suppress OPN in THP-1 macrophages at a non-AP-1 site
at 89 to 95 in the OPN promoter.11 The importance
of this site has not been confirmed. Further studies are
necessary to detail the mechanisms by which PPARg ligands
suppress OPN, which can ultimately attenuate fibrosis and
inflammation.
In this study, OPN stimulated TGF-b in vitro, while the
effect of OPN deletion in vivo decreased glomerular TGF-b.
Thus, in addition to promoting tissue macrophage recruit-
ment, cell growth and adhesion, OPN may enhance
fibrogenesis by direct TGF-b stimulation and subsequent
extracellular matrix production.46 Furthermore, rmOPN
activated ERK/MAPK and JNK (through c-Jun activation)
signaling pathways, which are known to stimulate TGF-b
production in mesangial cells.8,47 OPN antibodies inhibited
glucose-induced TGF-b expression, suggesting that OPN
mediates some of the adverse effects of glucose. In a previous
study, hyperglycemia and hypoxia additively stimulated OPN
mRNA and protein expression, leading to increased collagen
IV and cell proliferation8,22 that were blocked by neutralizing
antibody to either OPN or b3-integrin receptor, pointing to a
profibrotic role for OPN. Taken together, these data suggest
that modalities that decrease OPN or block b3-integrin may
be useful therapeutic targets in DN.
In a mouse model of obstructive uropathy, Ophascharoensuk
et al.48 demonstrated decreased renal interstitial fibrosis in
OPN/ mice, and decreased macrophage accumulation.
Indeed, inflammation contributes to tissue fibrosis, and
macrophages from OPN/ animals demonstrate increased
apoptosis, decreased migration and altered inflammatory
behavior compared with macrophages of controls.49 Recently,
the role of inflammation, and particularly macrophage
chemoattractant protein-1 (MCP-1) was examined in the
development of DN in both STZ-diabetic and diabetic db/db
mice.50–52 Lack of MCP-1 was associated with a marked
reduction in glomerular and interstitial macrophage accumula-
tion, albuminuria, and renal fibrosis.50,51 We previously
demonstrated in the heart that (1) OPN is upregulated in
cardiac hypertrophy along with brain natriuretic peptide, (2)
rmOPN promotes cardiac fibroblast adhesion to a variety of
extracellular matrices, and (3) OPN/ mice have attenuated
AngII-induced cardiac fibrosis, suggesting that OPN mediates
interstitial fibrosis in the heart similar to its impact in the
kidney.53 However, in the heart, AngII promotes fibrosis, in
large part, by promoting a substantial interstitial and
perivascular inflammatory response,54,55 that is not as profound
as the inflammatory response in DN.56,57 Thus, direct OPN
actions in mesangial cells to stimulate TGF-b and matrix
deposition appear to be important mechanisms by which OPN
contributes to DN.
In summary, mounting evidence supports the role of OPN
in mediating the fibrotic changes associated with glomerulo-
sclerosis and interstitial fibrosis, hallmarks of DN. OPN may
be a novel therapeutic target in profibrotic diseases. RAAS
activation is associated with enhanced tissue OPN expression,
and RAAS blockade downregulates OPN expression58,59 and
thus may have additive or synergistic actions with PPARg
activation in decreasing renal OPN and proteinuria. The
present observations support the development of clinical
studies examining the potential protective effects of PPARg
ligands in both type 1 and 2 DN.
MATERIALS AND METHODS
Animals
Genetic models of type 1 and 2 diabetic OPN/ mice were bred
into JAX#003548 C57BL6-Ins2akita/J and JAX#000642 BKS.Cg-
Dock7 mþ /þLeprdb/J (purchased from Jackson Labs, Bar Harbor,
ME, USA), respectively. The presence or absence of the Ins2akita
mutant within each colony were littermates, Leprdb heterozygotes
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Figure 7 |OPN deletion protects against albuminuria in type 1
Ins2akita/þ and type 2db/db diabetic mice. OPN/ mice were
bred against Ins2þ /þ ; Ins2akita/þ and db/m (Leprdb/þ ) and db/db
(Leprdb/db) mice to generate genetic models of type 1 and 2
diabetes OPN-null mice and their corresponding littermates.
Animals were placed in metabolic cages after 2, 3, and 4 months
for urine collection. (a and b) In both models, albumin-to-
creatinine ratio (mean±s.d.) was significantly higher in diabetic
versus non-diabetic OPNþ /þ mice, *Po0.001, #Po0.01, NS, not
significant.
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were bred together to produce leprdb/db and leprþ /þ littermates
within OPN-expressing and OPN-deficient mice, which were
produced after three generations (Figures 5 and 6) and the colony
mates were controls. Diabetic db/db mice were fed rosiglitazone
(367 mg/kg/day), pioglitazone (300 mg/kg/day) or administered
insulin (1–4 U/kg) for comparable plasma glucose (B300 mg/dl).
Breeding pairs of OPN/ (129Black Swiss background) with the
mutated secreted phosphoprotein 1 (spp-1) gene for OPN were a gift
of R. Johnson and C.M. Giachelli (University of Florida, Gainesville,
FL, USA) with permission from L. Liaw (Maine Medical Center
Research Institute, South Portland, ME, USA).49,60 OPNþ /þ
and OPN/ mice were made diabetic by intraperitoneal STZ
(2.5 mg/kg). Mice were fed normal chow (Harlan 8604) ad lib at 12 h
light–dark cycles. Procedures were approved by the UCLA Animal
Research Committee and complied with appropriate federal, state,
local and institutional regulations.
Physiological measurement
Fasting plasma glucose from retro-orbital blood for glucose oxidase
reaction (Beckman Glucose Analyzer 2, Beckman Instruments,
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Figure 8 |OPN deletion protects against renal changes in type 1 Ins2akita/þ and type 2 db/db diabetic mice. At the end of the study,
kidney sections were used for analysis by PAS staining (a–d) and IHC of collagen IV and fibronectin and quantified. (e–l) The figures show
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Fullerton, CA, USA) on X3 repeated fasted blood samples were
measured and averaged. Weekly blood pressures were obtained from
trained, prewarmed mice by computerized, non-invasive tail-cuff
system (BP 2000 Blood Pressure Analysis System, Visitech System,
Apex, NC, USA). Animals were placed in humidified metabolic
cages for 24 h urine collection. Urinary creatinine and albumin
measurements were performed by Creatinine Companion and
Albumin M assay (Exocel, Philadelphia, PA, USA), respectively.
Kidneys were dissected, weighed, and tibia lengths were measured
to reduce effects of changes in body weight.
Periodic acid Schiff staining
At the end of treatment (age 16 weeks), kidney tissues were
immersion-fixed in 4% paraformaldehyde/phosphate-buffered sal-
ine, and embedded in paraffin. Sections (3 mm) were stained with
PAS for matrix (http://www.amdcc.org). Twenty-five glomeruli from
X5 animals per group were digitally quantified and reported as %
mesangial area.
Immunohistochemistry staining
Fibronectin and collagen IV expression in kidney sections was
detected by IHC, by avidin–biotin immunoperoxidase (ZYMED
detection system; Carlsbad, CA, USA). Paraffin-embedded 4 mm
sections were deparaffinized with xylene, rehydrated in descending
series of ethanol and boiled in 10 mmol/l citrate buffer. Endogenous
peroxidase was applied in 10% hydrogen peroxide in phosphate-
buffered saline  10 min and sections were blocked with avidin/
biotin blocking reagent. Primary antibodies against mouse fibro-
nectin and collagen IV (1:200; Lab Vision, Fermont, CA, USA) or
phosphate-buffered saline (negative control) were incubated over-
night at 41C. The sections were washed in phosphate-buffered
saline, incubated with secondary antibodies, washed and incubated
 30 min with Vectastain ABC reagent (Burlingame, CA, USA).
Bound antibodies were detected using substrate-chromagen mixture
for a brown color. The sections were stained with hematoxylin
solution, dehydrated, and evaluated by light microscopy. Fibro-
nectin and collagen IV staining was quantified by scanning 15
non-overlapping randomly selected fields/kidney sections at  200
magnification (with exclusion of blood vessel areas). The percentage
of the immunohistochemical signal was measured by computerized
image analysis system (Image Pro-Plus, Media Cybernetics, Silver
Spring, MD, USA).
Western blot analysis
Western blot analysis was performed using standard procedures.
Mouse glomerular cores were isolated by the sieving method.61
Briefly, mouse kidney cortex was excised and passed through sieves
of 60, 100, and 200 mesh for glomerular tufts of glomerular cells.
Glomerular core protein (40–100mg) was separated by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis. Membranes were probed
with primary antibody to fibronectin (mouse anti-fibronectin anti-
body, 1:100; Lab Vision, Fremont, CA, USA), TGF-b (rat anti-TGF-b
antibody; 1:100 dilution; BD Pharmingen, San Diego, CA, USA),
phosphorylated and total ERK/MAPK, JNK and c-Jun. Membranes
were incubated with secondary antibody (anti-mouse IgG, 1:2500,
Cell Signaling Technology, Danvers, MA, USA; or anti-rat IgG,
1:2000, Amersham Biosciences, Piscataway, NJ, USA). The signals
were scanned and quantified by ArcSoft photostudio v.5
software (Fremont, CA, USA). Following enhanced chemilumines-
cence detection, the membranes were stripped and proteins
rehybridized with anti-b-actin antibody (1:3500, Gene Tex, San
Antonio, TX, USA). Protein levels expressed as protein/b-actin ratio
minimized loading differences.
Quantitative RT-PCR
Total RNA from glomerular cores or cell lysate isolated by RNeasy
(Qiagen, Valencia, CA, USA) was treated with DNase (Promega,
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Figure 9 |OPN induces TGF-b in a dose-dependent and time-
dependent manner. Stable mouse mesangial cells (MES 13) were
used for in vitro experiments for mRNA and protein expression
(representative western blots shown). (a and b) Mesangial cells
were treated with increasing concentrations of rmOPN
(0–10 nmol/l) for 24 h; n¼ 4, *Po0.05. (c and d) Mesangial cells
were treated with rmOPN (10 nmol/l) for up to 24 h, n¼ 4,
*Po0.05 versus 4 h treatment. (e and f) Mesangial cells were
grown in glucose (4 or 30mmol/l) or pretreated for 2 h with
increasing concentrations of OPN antibody, n¼ 4. After 48 h, cells
were lysed and the protein used in western blot analysis. The
figure shows a representative western blot and quantification of
TGF-b1/b-actin signal, *Po0.05 versus cells in glucose 4mmol/l.
rmOPN, recombinant mouse osteopontin.
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Madison, WI, USA). Reverse transcription was performed using
TaqMan Reverse Transcription Reagents (Applied Biosystems, Foster
City, CA, USA). The synthesized cDNA was quantified by quantita-
tive RT-PCR using ABI Prism 7700 Sequence Detection System
(Applied Biosystems) as follows: 501C  2 min, 951C  10 min,
951C  1 s and 601C  1 min for 40 cycles using primers
(200 nmol/l) and probes (100 nmol/l). PCR amplifications of
20 reagent of proprietary reverse and forward primers and
probes for OPN (25ml; ABI, Mm00437304_m1, Assay-on-Demand
Gene Expression Products, Applied Biosystems) were performed in
triplicates. Gene expression compared with GAPDH was measured
simultaneously, n¼ 4 separate experiments.
Mouse mesangial (MES-13) cell culture
Stable mouse mesangial cells (American Type Culture Collection,
Manassas, VA, USA) were grown to 90% confluence, serum-starved
(0.05% fetal bovine serum)  18–24 h and treated with insulin
(1mmol/l), angiotensin II (AngII; 1mmol/l), pioglitazone (5 mmol/l)
or rosiglitazone (5mmol/l) for 24–48 h or rmOPN (0–10 nmol/l;
R&D Systems, Minneapolis, MN, USA) for up to 24 h. Cells were
lysed and RNA and protein were isolated for OPN expression by
quantitative RT-PCR and western blot.
Statistical analysis
Data are expressed as the mean±s.e. of the mean or s.d. where
stated. We assessed differences between control and treated groups
using Student’s t-test and between multiple groups using analysis
of varincce with Tukey’s multiple-comparisons post-test where Po0.05.
Data sets were tested for normality and statistical significance (Po0.05)
using InStat Statistical software (San Diego, CA, USA).
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